Replicel Is On Fire Lately — Data In Feb.
- Thread starter That Guy
- Start date
tress_dreams
Member
- Reaction score
- 24
I'm cautiously optimistic that some level of maintenance can be achieved from replicel. I'd pay for it in order to compliment the .25mg daily finasteride I take.
I doubt it's any sort of miracle. Word would have gotten out over the last 5+ years. They probably wouldn't be working on complimentary lines in aging and tendonitis either. These other lines of research seem like a way to support the companies valuation and their salaries as a hedge against the less than extraordinary promise that is their hair efforts.
I'll still pay 1k-1.5k for maintenance treatments once a year. I doubt I'm alone. Here's hoping we at least get that.
As an aside, the stock is an interesting play too; so little market cap. If any of these lines of research pan out in a serious way allergan and the likes will gladly pay massively. With them releasing multiple pieces of data at once it limits the potential downside when the hair data is shown less effective. So limited downside risk and potential upside return if you can buy-n-hold for years.
I doubt it's any sort of miracle. Word would have gotten out over the last 5+ years. They probably wouldn't be working on complimentary lines in aging and tendonitis either. These other lines of research seem like a way to support the companies valuation and their salaries as a hedge against the less than extraordinary promise that is their hair efforts.
I'll still pay 1k-1.5k for maintenance treatments once a year. I doubt I'm alone. Here's hoping we at least get that.
As an aside, the stock is an interesting play too; so little market cap. If any of these lines of research pan out in a serious way allergan and the likes will gladly pay massively. With them releasing multiple pieces of data at once it limits the potential downside when the hair data is shown less effective. So limited downside risk and potential upside return if you can buy-n-hold for years.
- Reaction score
- 374
1. Proof or source? Surely you smart guy who quotes studies all over the thread but doesn't even know "by three orders of magnitude" means x1000 has the strongest brain on this forum (just happen to come across that post, don't take me for those psychos who search through a thousand posts to find fault in someone).
2. You clearly indicated that.
3. Some? To what percentage? Does that change the big picture that investors are in for the money and are reluctant to move forward unless ENOUGH interest is foreseeable, which has been proven time and time again, e.g. with aderan and intercytex?
4. Agree.
5. This is irrelevant. Any one who can read can tell what you mean from the context. And just as you said, we are talking about the general moods of the public instead of forum readers.
Please don't type back to continue this useless debate and let's spend our energy on what this forum section is meant for.
- Reaction score
- 374
Despite your attacking while refusing to respond to my well grounded previous post, I'll just quote your post here for the other (educated)forum members to judge.
You're on my ignore list now. Keeping posting and embarrassing yourself is welcomed.
Breaking Bald
Established Member
- Reaction score
- 61
Why must we be tortured, when are they going to release the data!? I've noticed that they have been deleting people's comments on their facebook page as well.
br1
Senior Member
- Reaction score
- 2,163
Let's hope so. But nobody knows anything, until their data is released...
- Reaction score
- 50
We could do a poll too see if members think you've ever cracked a smile?
LOL.
Replicel gives me NOTHING to smile about. I think lots of posters are unhappy with Replicel right about now.
My hopes right now are with Follica.
Last edited:
These goofs actually used this pic https://mobile.twitter.com/RepliCel...4?ref_src=twsrc^google|twcamp^serp|twgr^tweet
I mean even if it did have decent results, not professional at all. Using a prince as an example? No class
- Reaction score
- 217
He is just a human with human's problems.
tress_dreams
Member
- Reaction score
- 24
I'm very confident at this point that Replicel is a bullshit company and they're just milking the penny stock for the options:
I find the lack of current employees rather suspicious. There are a large number of former employees. I haven't even begun reading over the shoddy financial and corporate documents. OTC financials, it's going to be entertaining I'm sure.
I think they've made a profession of chairing, directing, and otherwise leading failed biotechs that are publicly traded under these loosely regulated exchanges. The options are motivation enough, just bleed investors for a few more years. Being sure to publish data in speculative bull markets that make the past research seem viable enough to propel the stock. Being rather "lawyerly" in the process so as not to commit any sort of fraud. All quite legal.
- linkedin shows 5 employees - 2 chairman, a director, and the ceo. NO research positions listed. *doesn't mean there aren't more but suspiciously absent*
- Buckler (CEO) and Rogers (Director) both were/are lawyers. The chairman, Jensen, appears to be in securities law.
- All three of the above named individuals ALSO have other jobs.
- Buckler's other job is as CEO of another biotech penny stock called Hemostemix. Let's take a look at how that's done since 2013 when he started as CEO:
-
I find the lack of current employees rather suspicious. There are a large number of former employees. I haven't even begun reading over the shoddy financial and corporate documents. OTC financials, it's going to be entertaining I'm sure.
I think they've made a profession of chairing, directing, and otherwise leading failed biotechs that are publicly traded under these loosely regulated exchanges. The options are motivation enough, just bleed investors for a few more years. Being sure to publish data in speculative bull markets that make the past research seem viable enough to propel the stock. Being rather "lawyerly" in the process so as not to commit any sort of fraud. All quite legal.
- Reaction score
- 11
But what about Shiseidos involvement and investment though ?
tress_dreams
Member
- Reaction score
- 24
I'm curious too. I want to know if Shseido is obligated to share their research and advancements with Replicel. If not they may have merely procured Replicel's original methodologies (through the partnership) to bootstrap, augment or otherwise support their own research. Making several small investments and partnerships with potential solutions in a space doesn't seem unusual. Anyone privileged to the terms of the contract? I want to believe Shseido is still advancing their own research/techniques.
Follisket
Established Member
- Reaction score
- 288
If their results turn out sh*t and the whole thing gets canned, I hope they get torn to shreds.
With the tweets and statements they've been making all the while they had insight into the results -
That kind of deception isn't just "clever marketing", it isn't "business" or "cunning". It is a sick, psychopatic abuse of people's mental health.
For f***'s sake, we're not talking about a new flavour of ice cream or a fun new gadget here. The disorder can fuel suicidal thoughts yet someone wants to make fraudulent money off it?!
With the tweets and statements they've been making all the while they had insight into the results -
That kind of deception isn't just "clever marketing", it isn't "business" or "cunning". It is a sick, psychopatic abuse of people's mental health.
For f***'s sake, we're not talking about a new flavour of ice cream or a fun new gadget here. The disorder can fuel suicidal thoughts yet someone wants to make fraudulent money off it?!
As sketchy as it is their early results from the initial trial did show hair regrowth in a majority of patients. I'm skeptical of Replicel but at the same time a company worth billions bought the rights for it in Asia and even has set up an entire institute in dealing with the product. These are people with phd's and master degrees who have spent years studying micro biology and the likes. It's not to far off to think that they have a good shot with getting it to work.